Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2015, Article ID 938628, 11 pages
Clinical Study

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

1Desmond Tutu HIV Foundation, UCT Medical School, P.O. Box 13801, Mowbray, Cape Town 7705, South Africa
2Private Practice, 3535 San Dimas Street, Suite 24, Bakersfield, CA 93301, USA
3Parexel International, University of the Free State, Campus Avenue South, Bloemfontein, Free State 9301, South Africa
4Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA
5Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium

Received 11 September 2014; Revised 26 November 2014; Accepted 9 December 2014

Academic Editor: Andrea Mangano

Copyright © 2015 Catherine Orrell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [2 citations]

The following is the list of published articles that have cited the current article.

  • Bruce Green, Herta Crauwels, Thomas N. Kakuda, Simon Vanveggel, and Anne Brochot, “Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine,” Clinical Pharmacokinetics, 2016. View at Publisher · View at Google Scholar
  • Eduardo Arathoon, Asad Bhorat, Rodica Silaghi, Herta Crauwels, Ludo Lavreys, Lotke Tambuyzer, Ben Van Baelen, Simon Vanveggel, and Magda Opsomer, “Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.,” SAGE open medicine, vol. 5, pp. 2050312116686482, 2017. View at Publisher · View at Google Scholar